TACI, a member of the TNF Receptor superfamily, is expressed in the small intestine, spleen, thymus, peripheral blood leukocytes, activated T cells, and resting B cells. TACI binds to both APRIL and BAFF and can stimulate the activation of transcription factors; NF-kappaB, AP-1, and mediates calcineurin dependent activation of NF-AT (nuclear-factor of activated T cells). TACI also plays a key role in the stimulation of B and T cell function. Soluble TACI inhibits APRIL- stimulated proliferation of primary B-cells by blocking the binding of APRIL to the membrane anchored TACI receptor. Recombinant human TACI is a soluble 160 amino acid polypeptide (17.8 kDa) comprising the TNFR homologous cysteine rich extracellular domain of the TACI protein.
Human TNFRSF13B expressed in E.coli
CAT# CSC-CTK0515-20 (20 μg); CAT# CSC-CTK0515-100 (100 μg)
Greater than 98% as determined by SDS-PAGE and HPLC analysis.
Determined by its ability to block human BAFF induced T2B cell survival using a concentration range of 1.0-3.0 μg/ml.
Less than 1 EU/μg.
Lyophilized from a sterile-filtered solution with no additives.
Please centrifuge product briefly before opening the vial. Reconstitute in sterile, ultra-pure water to a concentration of 0.1-1.0 mg/ml. This solution can be diluted into other aqueous buffers and stored at -20°C for future use.
Storage & Stability
The lyophilized powder, though stable at room temperature for up to 3 weeks, is best stored desiccated at -20°C. Reconstituted TACI should be used immediately or stored in undiluted working aliquots at -20°C. Avoid repeated freeze / thaw cycles.
If you use this products in your scientific publication, it should be cited in the publication as: Creative Bioarray cat no. If your paper has been published, please click here to submit the Pub Med ID of your paper to get a coupon.